Preoperative SBRT for the Primary Lesion of Breast Cancer
Preoperative SBRT for the Primary Lesion of Breast Cancer: SBRT for Primary Lesion of Breast Cancer, Radiation Dose: Primary Lesion ≤3 cm, GTV 24Gy/3F; Primary Lesion \>3 cm, GTV 30Gy/5F.
Study summary
This study focuses on preoperative treatment modalities for luminal-type locally advanced breast cancer. Based on modern precision radiotherapy technologies such as MRI-Linac, CyberKnife, and VMAT, it aims to compare the pCR rate, breast conserving surgery (BCS) rate, progression-free survival (PFS), and treatment-related side effects between preoperative neoadjuvant chemotherapy and preoperative neoadjuvant SBRT combined with chemotherapy in patients with this type of breast cancer. The goal is to provide new strategic options for the preoperative treatment of luminal-type locally advanced breast cancer.
Eligibility
Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria:
1. Pathologically confirmed invasive breast cancer ;
2. Breast MRI showing stages IIB to IIIC (2017 AJCC 8th edition staging);
3. Clinical staging confirmed by chest MRI and/or axillary ultrasound, as well as CT scans of the neck, abdomen, and pelvis, and bone scintigraphy, including T and N staging and assessment of distant metastasis;
4. Karnofsky performance score ≥80 or ECOG performance status of 0-1;
5. No history of allergies to doxorubicin, cyclophosphamide, paclitaxel/docetaxel;
6. No prior exposure to radiotherapy, chemotherapy, endocrine therapy, targeted therapy, or immunotherapy.
Exclusion Criteria:
1. History of malignancy at other sites, excluding curable non-melanoma skin cancer and carcinoma in situ of the cervix;
2. Inability to complete MRI;
3. Inflammatory breast cancer;
4. Bilateral or multifocal primary tumors;
5. Active infection currently present; clinically evident heart disease; myocardial infarction or cerebrovascular accident within 6 months prior to enrollment.
Primary outcome measure(s)
pCR — From enrollment to one month after surgery Pathological Complete Response Following Surgery
Trial sites (1)
Facility
City
Region
Status
Sichuan Cancer Hospital
Chengdu
Sichuan
Recruiting
More Sichuan Cancer Hospital and Research Institute trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.